LTRN
Lantern Pharma Inc. (LTRN) 10Y Growth Potential Analysis (2026)
No material changes this month.
Valuation
0Valuation is not meaningful on a TTM basis because revenue, margins, and cash flow are effectively zero or negative, leaving EV/Sales at 0 and EV/EBITDA at -0.97.
The balance sheet is small and fragile, with a current ratio of 1.96 but negative tangible book value per share (-0.26) and net current asset value (-3.36M).
Growth
0No evidence of durable growth is visible in the TTM metrics because revenue per share is 0 and profitability remains deeply negative.
Operating efficiency is weak, with ROA at -2.17% and ROIC at -3.58%, indicating the business is not compounding capital.
Profitability
0Margins are effectively 0 across gross, operating, EBITDA, pretax, and net profit, showing no current earnings power.
Returns remain negative across ROE (-4.56%), ROA (-2.17%), and ROIC (-3.58%), confirming persistent unprofitability.
Financial Health
0Liquidity is acceptable in the near term with a current ratio of 1.96 and cash ratio of 1.54, but the capital base is weak given negative equity and tangible book value.
Debt appears minimal relative to market cap and assets, but solvency metrics are distorted by the negative earnings base and do not offset the weak equity position.
Market Sentiment
0No recent news was provided, so there is no fresh catalyst to improve sentiment.
The market is still pricing a highly distressed, low-quality earnings profile, as reflected in negative earnings yield and negative free cash flow yield.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Lantern Pharma Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.